Planned Development of MelVac platform

Months 0-6

Clinical product synthesis and testing

Months 6-12

Pre-Phase I development

Months 12-24

Initiation and completion of Phase I

Overall development

Months 0-6: Clinical product synthesis and testing

Activities

  • GMP synthesis
  • Stability
  • Toxicology
  • Formulation

Output

  • IL-2 recombinant vaccinia virus
    and melanoma cell lysates

Back to top

Months 6-12: Pre-Phase I development

Activities

  • Expansion of IP
  • Animal model
  • Phase I clinical trial

Output

  • Other cancer and uses
  • Phase I
  • Immunotherapeutic vaccine

Back to top

Months 12-24: Initiation and completion of Phase I

Activities

  • Clinical development of
    MelVac platform

Output

  • Licensing of MelVac to strategic partner
  • Continued development of combination therapy

Back to top

Overall development

Activities

  • Combination Multicenter trials
  • Expanded IP testing autologous trial

Output

  • Phase I/ II trial
  • Autologous and allogeneic vaccine
  • efficacy testing

Back to top